Paired tumor-germline testing can enhance patient care—with guidance from genetics specialists

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

In May, the American Society of Clinical Oncology released guidelines on the use of germline genetic testing panels in concert with tumor testing for cancer patients.1 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Rebecca Sutphen, MD
Co-founder, chief medical officer, InformedDNA
Table of Contents

YOU MAY BE INTERESTED IN

Unfold AI, an AI prostate cancer mapping and clinical decision support platform, is now included in Medicare’s Physician Fee Schedules across the West Coast and Mountain West regions. The regional expansion of Medicare payment for the tool gives urologists and care teams clearer reimbursement pathways in physician office settings, an area that has historically lagged behind hospital outpatient settings for emerging technologies.
Rebecca Sutphen, MD
Co-founder, chief medical officer, InformedDNA

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login